Navigation Links
Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Date:10/29/2007

Application of ZFN Technology in Stem Cells has Potential to Yield High

Value Research Reagents and Therapeutic Products

ST. LOUIS and RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) and Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication of data demonstrating the use of Sangamo's ZFP Nucleases (ZFNs) for "gene-editing" in human stem cells. This work represents a significant advance in the ability to specifically and efficiently modify the human genome in stem cells potentially enabling the efficient generation of stem cell lines for use as models of human disease for medical research and for drug testing. In addition to its use in the generation of valuable research reagents, the technology has potential in the therapeutic application of stem cells.

The work, which was carried out in the laboratory of Luigi Naldini, M.D., Ph.D. at the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy, in collaboration with Sangamo scientists, was published in Nature Biotechnology as an advance online publication (http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt1353.html).

"This is a significant advance for both research and the potential therapeutic use of stem cells," stated Dr. Naldini, a senior author of the study. "Stem cells are the body's natural resource for regeneration and re
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
2. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
6. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
7. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ire/ -- TessArae® LLC, a global leader in res... the launch of new integrated product solutions fo...uman hereditary diseases. The combination of Tess...with novel nucleotide sequence basecalling algorit...l targeted mutations in multiple genes of a syndro...
(Date:11/9/2009)...- AMD LASERS just announced that industry leading ... the position of Medical Director. In his new rol...search and development of new soft and hard tissue...nuing education credits, authoring articles for re...turing and seminar engagements. ,, "We are very...
(Date:11/9/2009)...RNewswire/ -- Unwavering from its pursuit of produ...oday,s economic climate, Lutronic, Inc., a leading..., introduces the MOSAIC CO2, a full-featured fract...he MOSAIC CO2 offers many of the features unique t...ing and stamping operation modes and patented Cont...
Breaking Medicine Technology:TessArae Delivers Lower Cost Option to Genetic Testing Market 2AMD LASERS Names Dr. James Jesse as Medical Director 2Lutronic(R) Unleashes the New MOSAIC CO2 2Cell Therapeutics Inc 28CTI 29 to Report Second Quarter Financial Results on August 6 53686 1Climate change poker 3A The barriers which are preventing a global agreement 9478 1Climate change poker 3A The barriers which are preventing a global agreement 9478 2delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9476 1delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation 9476 2
...ceuticals Inc.,announced today on the occasion of ...International Conference in San Francisco that its...howed synergistic effects,with certain standard ch...7). In vitro data showed significant (p<0.001... cells with combinations of docetaxel and,SF1126, ...
... data presented at AACR-NCI-EORTC ...Cell Therapeutics,Inc. (CTI) (Nasdaq and MTAX: CTI...subsidiary of CTI, announced new preclinical data ...h annual AACR-NCI-EORTC Symposium. "These studies...ic,tumor types with a higher likelihood of demonst...
Other Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
(Date:11/9/2009)...apy to improve letter formation could boost self-e...9 (HealthDay News) -- Autistic children are more l...ble forming letters, than those without autism, re...dren, aged 8 to 13. Half of the study participants...dren scored within the normal range for perceptual...
(Date:11/9/2009)..., SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ -....com , announced today that Novartis, a US$41 bill... an 85% stake in HTDS, H1N1 Vaccine partner, Zheji...125 million. Novartis of Switzerland will begin a ...ms: the company will dramatically increase its inv...
(Date:11/9/2009)... New study highlights positiv... , Rosemont, IL (Vocus) N...e and bone health decreases. Recent research has h...supplements to help prevent these issues. However,...sue of Sports Health: A Multidisciplinary Approac...
(Date:11/9/2009)..., March of Dimes Names 2010 National Ambassador ...ewswire/ -- Joshua Hoffman of Weston, Fla., was bo... that doctors could not say whether he would survi... Today, the 6-year-old was named March of Dimes 20...ie Hoffman, recalls, "My first minutes of motherho...
(Date:11/9/2009)...l study reports some people went from incapacitate...9 (HealthDay News) -- Electrical stimulation of a ...reatment for severe depression, say German researc...s accumbens area of the brains of 10 people. This...at ensures that people remember good experiences a...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2
...care, Inc.,(OTC Bulletin Board: TONJ), a premier p...in China, reports that its hospital are enjoying a...Sichuan province., Due to its status as a private...quake victims, many of whom have little,or no insu...
...ly 80 percent of adults,experience back pain at so...of South Carolina this month will launch a free, b...Back pain is one of the most common medical proble... said BlueChoice,HealthPlan Chief Medical Officer ...
...ents with testicular cancer are cured nowadays, bu...er survivors, the medical profession and national ...cer Trust,s Fifth International Conference on Teen...pment and director of the germ cell tumor and lymp...
...he Endocrine Society will present Ronald S. Swerdl...medical Research Institute at Harbor-UCLA Medical ...r Award during its annual convention June 15-18 in...docrinology, bestows this honor to a single recipi...
...use online programs as well as drugs to help probl...- Insomnia among U.S. combat veterans returning fr... chronic insomnia, according to University of Pitt... vets displayed significantly more severe disrupti...
...(NYSE: MYL ),announced today that it has signed a...d. (NATCO) for NATCO,s glatiramer acetate pre-fill...R), which is used to treat,multiple sclerosis. The...nd includes an option to expand into additional,te...
Other Medicine News:Health News:Tongji Healthcare Services Reports Influx of Patients 2Health News:BlueChoice HealthPlan to Launch Back Care Program 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 3Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 4Health News:LA BioMed investigator wins Distinguished Educator Award 2Health News:Combat Vets Display Severe Sleep Disorders 2Health News:Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R) 2
...rovides fingertip ratchet disengagement allowing s...rument program offers state-of-the-art quality in ...taining strength and durability. Low profile cutti...paces. Series I instruments are available in just ...
...rovides fingertip ratchet disengagement allowing s...rument program offers state-of-the-art quality in ...taining strength and durability. Low profile cutti...paces. Series I instruments are available in just ...
...rovides fingertip ratchet disengagement allowing s...rument program offers state-of-the-art quality in ...taining strength and durability. Low profile cutti...paces. Series I instruments are available in just ...
...rovides fingertip ratchet disengagement allowing s...rument program offers state-of-the-art quality in ...taining strength and durability. Low profile cutti...paces. Series I instruments are available in just ...
Medicine Products: